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Abstract
Background: Viral hepatitis has emerged as a major public health problem leading to disproportionate degrees of morbidity and
mortality worldwide.
Objectives: This study describes epidemiology of hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis C virus (HCV), and
associated risk factors in patients with acute hepatitis symptoms in southwest of Iran (Ahvaz).
Methods: A total of 150 serum samples from patients with elevated serum aminotransferase levels were subjected to serological
and molecular assays.
Results: The sero-prevalence of HAV, HBV, and HCV was 79.3%. Furthermore, HAV, HBV, and HCV nucleic acids were detected in 28%,
18.7%, and 22.7% of samples, respectively. All HAV cases were categorized in the IB genotype and HBV isolates belonged to genotype
D. Hepatitis C virus RNA-positive samples were clustered in genotypes 1a (38.3%) and 3a (61.7%). The authors found that some risk
factors, such tattooing and traveling to endemic areas, had a crucial role in rising of viral hepatitis frequency in Ahvaz city.
Conclusions: These results document the prevalence of circulating viral hepatitis in Ahvaz city and may draw attention to the
necessity for a comprehensive program to control viral hepatitis in this region.
Keywords: Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Molecular Epidemiology, Risk Factor,
Polymerase Chain Reaction, Tattooing
1. Background
Viral hepatitis is a growing global public health con-
cern both in developed and developing countries. In 2013,
viral hepatitis was the seventh leading cause of death
worldwide (1). There are several unrelated hepatotropic
viruses causing wide spectrum of liver diseases ranging
from simple steatosis infection to hepatocellular carci-
noma (HCC). Hepatitis A virus (HAV), hepatitis B virus
(HBV), and hepatitis C virus (HCV) are the major causative
agents of acute viral infections. Hepatitis A virus infection
occurs mostly in children, and accounts for an estimated
1.5 million cases each year. Unlike HBV and HCV, as the
main chronic hepatitis viruses, HAV transmits enterically
and the following infection is self-limiting and never leads
to a chronic hepatitis (2, 3).
Unfortunately, despite therapeutic advances and effec-
tive vaccine for HBV, there are nearly 2 billion infected peo-
ple and more than 240 million chronic carriers, world-
wide (4). In addition, about 170 million people have been
infected chronically by HCV and approximately 700000
deaths occur annually due to HCV-related liver disease (5).
It must be noted that chronic carriers of HBV and HCV
viruses are the source of new infections and serious liver
diseases, such as cirrhosis, HCC, fulminant hepatitis failure
(FHF), and encephalopathy due to super-infection caused
by other hepatitis viruses, such as HAV or HDV (6-10).
Serological methods for detection of HBsAg and anti-
HCV are routinely used in diagnostic laboratories. How-
ever, because of problems with serological assays, such as
window period and occult hepatitis B/C infections among
serologically negative patients, nucleic acid tests (NATs)
are the gold standard for diagnosing of infections and fol-
lowing the treatments.
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2. Objectives
The authors performed a molecular-based epidemio-
logical survey to detect and evaluate HAV, HBV, and HCV in-
fections and associated risk factors among patients with
acute hepatitis manifestations.
3. Methods
3.1. Ethics Statement
This work was registered with grant No. GD-94118 and
financially supported by infectious and tropical diseases
research center, faculty of medicine, Ahvaz Jundishapur
University of Medical Sciences, Ahvaz.
3.2. Patients and Samples
The current study was conducted at the virology de-
partment of the Faculty of Medicine, Ahvaz Jundishapur
University of Medical Sciences. During March to December,
2016, a total of 150 sera were collected from patients with
elevated serum aminotransferase levels (at least 2 times
greater than the upper reference value). All samples be-
longed to patients, who attended clinical laboratories in
Ahvaz (Pasteur and Jahad Daneshgahi). Patients with fatty
liver disease, cirrhosis, hepatocellular carcinoma, and ge-
netic and metabolic disorders were excluded.
3.3. Serological Testing
All sera were tested for anti HAV IgM, HBsAg, and
Anti-HCV, using the Enzyme Linked Immunosorbent Assay
(ELISA) kit (Diapro, Italy), then stored at -70°C until used for
DNA extraction and polymerase chain reaction (PCR).
3.4. Primers
5’-untranslated regions (5’-UTR) of HAV/HCV and X re-
gion of HBV (the highly conserved regions) were targeted
to PCR detection. VP1/2A junction, S, and core regions of
HAV, HBV, and HCV, respectively, were considered in geno-
type determination assays. By using NCBI Primer BLAST, it
was proved that the primers did not attach to any other
sequences except HAV, HBV, and HCV. The sequences of all
used primers for detection and genotyping were picked
from previous studies and shown in Table 1.
3.5. Nucleic Acid Extraction
All sera were subjected to nucleic acid extraction using
the high pure viral nucleic acid kit (Roche, Germany), ac-
cording to the manufacturer’s protocol.
3.6. Assay Optimization
After optimizing of primer concentrations and MgCl2
in a final reaction volume of 50 µL, PCR detection of HAV,
HBV, and HCV was performed. To determine the optimum
annealing temperature, gradient PCR was set at 55°C to
65°C. The best condition for each virus was obtained and
then samples along with negative (water) and positive con-
trols (previously known PCR-positive samples of HAV, HBV,
and HCV) were amplified.
3.7. HAV and HCV Genome Amplification
The reverse transcription polymerase chain reaction
(RT-PCR) with the use of QIAGEN One-Step RT-PCR kit for
HAV and HCV was set as follows: RT step 50°C/30 minutes,
initial activation at 95°C/15 minutes, 40 cycles of 94°C/30
seconds, 58°C/30 seconds, 72°C/30 seconds, and a final ex-
tension step of 72°C/10 minutes. Nested PCR step using 5µL
of RT-PCR step products and inner primer sets of HAV and
HCV was performed as follows: initial activation at 95°C/5
minutes, 40 cycles of 94°C/30 seconds, 58°C/30 seconds,
72°C/30 seconds, and a final extension step of 72°C/10 min-
utes. All reactions were performed at least twice and in the
presence of negative and positive controls. The final prod-
ucts were detected by electrophoresis on 2% agarose gel
containing DNA Safestain (Sinagene, Iran) under UV tran-
silluminator (VILBERANT LUMART, France). The sizes of the
PCR products were estimated according to the migration
pattern of a 100-bp DNA ladder (Sinagene, Iran) (Figure 1).
3.8. HAV and HCV Genotyping Assay
Polymerase Chain Reaction-positive samples at the de-
tection step were considered for genotype determination
assays. The RT-PCR and nested PCR reactions were car-
ried out like the previous step but this time with specific
primers for HAV VP1/2A junction and HCV core region.
3.9. HBV PCR Detection and Genotyping
Molecular detection of HBV DNA was set as follows: ini-
tial activation at 95°C/5 minutes, 40 cycles at 94°C/30 sec-
onds, 56°C/30 seconds, 72°C/30 seconds, and a final exten-
sion step of 72°C/10 minutes. Semi-nest PCR amplifications
were performed similar to the first step with different re-
verse primers. Hepatitis B virus genotyping was carried
out with the same conditions, but using other primer pairs
which targeted the S gene on HBV DNA-positive samples.
All reactions were performed in duplicate and in the pres-
ence of negative and positive controls. The final products
were detected by electrophoresis on 2% agarose gel and the
size of the PCR products were estimated by the migration
pattern of a 100-bp DNA ladder (Figure 1).
2 Jundishapur J Microbiol. 2018; 11(5):e63317.
Tabasi M et al.
Table 1. The Sequences of Used Primers for Detection and Phylogenetic Analysis
Virus Primer Sequence (5’ - 3’) Amplicon Size Target Agene Reference
HAV
Forward TTGGAACGTCACCTTGCAGTG 369 5’-UTR
(11)Reverse (outer) CTGAGTACCTCAGAGGCAAAC 5’-UTR
Reverse (inner) GAACAGTCCAGCTGTCAATGG 330 5’-UTR
BR-5a (outer) TTGTCTGTCACAGAACAATCAG 361 VP1/2A junction
(12)
BR-9a (outer) AGTCACACCTCTCCAGGAAAACTT VP1/2A junction
RJ-3b (inner) TCCCAGAGCTCCATTGAA 234 VP1/2A junction
BR-6a (inner) AGGAGGTGGAAGCACTTCATTTGA VP1/2A junction
HBV
Forward GTCCCCTTCTTCATCTGCCGT 139 X gene
(13)Reverse (outer) GTTCACGGTGGTCTCCATG X gene
Reverse (inner) ACGTGCAGAGGTGAAGCGAAG 118 X gene
Forward CGTGGTGGACTTCTCTCAATTTTC 417 S gene
(14)
Reverse GCCARGAGAAACGGRCTGAGGCCC S gene
HCV
Forward (outer) CACTCCCCTGTGAGGAACTACTGTC 306 5’-UTR
(15)
Reverse (outer) ATGGTGCACGGTCTACGAGACCTCC 5’-UTR
Forward (inner) TTCACGCAGAAAGCGTCTAGCCATG 276 5’-UTR
(16)
Reverse (inner) GCGCACTCGCAAGCACCCTATCAGG 5’-UTR
Forward (SC2) GGGAGGTCTCGTAGACCGTGCACCATG 440 Core gene
Reverse (AC2) GAGMGGKATRTACCCATGAGRTCGGC Core gene
Forward (S7) AGACCGTGCACCATGAGCAC 416 Core gene
Reverse (584) CCCATGAGGTCGGCRAARC Core gene
3.10. Sequencing Analysis
Positive results from the second rounds of PCR ampli-
fications were sequenced in both directions with the use
of big dye terminator v3.1 cycle sequencing kit (Applied
Biosystems), according to the manufacturer’s instructions.
Forward and reverse sequences were aligned by BioEdit se-
quence alignment editor version 7.0.5.3 and consensus se-
quences were obtained. The sequences were deposited at
GenBank under the accession numbers KX657751-KX657763
and MF673435-MF673437.
3.11. Phylogenetic Study
The MEGA6.06 software was used for phylogenetic
analysis. The multiple sequences alignment of retrieved
sequences from GenBank and the sequences of this study
were achieved by CLUSTAL W. The bootstrap neighbor join-
ing method with 1000 replicates was performed to deter-
mine the evolutionary distances.
3.12. Statistical Analysis
Data are reported as frequency and mean± standard
deviation (SD). The univariate and multiple logistic regres-
sion models (backward method) were used for analysis of
risk factors. For analysis, SPSS software 22 was used and
to test the hypotheses, the significance level was less than
0.05.
4. Results
4.1. Study Population
The study was carried out with 150 serum samples from
patients with symptoms of acute hepatitis. All patients had
high levels of alanine aminotransferase (ALT) and aspar-
tate transaminase (AST). The group included 54 (36%) fe-
males and 96 (64%) males with a mean age of 34.25± 9.167
years, ranging from 8 to 65 years. The mean ALT and AST lev-
els were 184.77± 120.12 and 90.86± 15.738, respectively. Dis-
tribution of risk factors among the 150 patients is shown in
Figure 2.
4.2. Serological Findings
Out of 150 samples, 49 (32.6%), 32 (21.3%), and 38 (25.3%)
were positive for anti-HAV, HBsAg, and anti-HCV, respec-
tively. The characteristics of acute hepatitis infection are
illustrated in Table 2.
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Figure 1. Electrophoresis pattern of PCR products of HAV, HBV, and HCV at the detection step. The products length were 330 bp for HAV (lane 1), 118 bp for HBV (lane 2, 3) and
276 bp for HCV (lane 4, 5). Lane 6: positive controls, lane 7: 100 bp DNA ladder.
7.30%9.30%
25.30%
24.70%
9.30%
31.30%
81.30%
Infected Family
Dental Care 
Surgery
Blood Transfusion 
Tattooing 
Travelling to Endemic Area 
IV Drug 
Figure 2. Risk factors distribution among 150 cases with acute hepatitis symptoms
4.3. HAV Molecular Detection and Genotyping
Forty-two of 150 samples (28%) were HAV RNA-positive
by RT-PCR. All positive samples were HAV IgM positive as
well. The mean range of ALT and AST of these patients were
229.74 IU/L and 98.48 IU/M, respectively. Genotyping via
specific primers for VP1/2A region as well as data analysis
suggested that all HAV isolates belonged to genotype IB
(Figure 3).
Table 2. Characteristics of the Different Acute Viral Hepatitis Infectionsa
Variable HAV RNA HBV DNA HCV RNA
Patients 42 (28) 28 (18.7) 34 (22.7)
Male 22 (52.4) 19 (68) 27 (79.4)
Age, y 24.3± 5.9 37± 4.9 40± 5.6
Mean value of ALT, IU/L 229.74± 143.6 165.9± 101.01 173.3± 137.6
Mean value of AST, IU/L 98.5± 22.1 83.8± 9.2 90.5± 14.4
aValues are expressed as No. (%) or mean± SD.
4.4. HBV Detection and Genotyping
Hepatitis B virus DNA was detected in 28 (18.7 %) of
150 samples, using semi nested PCR. All cases were HBsAg-
positive and the mean ALT and AST levels for these patients
were 165.9 IU/L and 83.8 IU/L, respectively. These positive
samples were subjected to additional PCR amplification
on the S gene for genotype determination. The multiple
alignments of obtained HBV sequences from this study
and those retrieved from GenBank database (representing
all 8 genotypes) indicated that all sequences were consis-
tent with genotype D (Figure 4).
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Figure 3. Neighbor-joining phylogenetic tree of HAV VP1-2A regions. The sequence from this study is marked and all sequences are defined by accession number / year/origin
of the strain, respectively.
4.5. HCV Detection and Genotyping
Overall, 34 of 150 (22.7%) samples were positive using
RT-PCR, aimed at the HCV 5’-UTR. The mean value of ALT
and AST levels in HCV RNA-positive patients were 173.3 IU/L
and 90.5 IU/L, respectively. For genotype detection, core re-
gion was amplified and comparison between acquired se-
quences and previously reported sequences indicated that
HCV RNA-positive samples could be classified to genotypes
1a (13/34, 38.2%) and 3a (21/34, 61.7%) (Figure 5).
5. Discussion
This research conducted a molecular-based epidemi-
ological survey to detect viral hepatitis in patients with
acute hepatitis. In the current study, the total seropreva-
lence of HAV, HBV, and HCV was found to be 79.3% (119/150).
There was not any difference in the prevalence of acute vi-
ral hepatitis among the patients, when stratified according
to gender. As indicated, in the present study, nearly 20% of
sera were negative for HAV, HBV, and HCV. It should be no-
ticed that there are also other viruses causing acute hepati-
tis, such as HDV, HEV, GB virus C, EBV, B19, herpes simplex
virus, etc., which were not considered in this survey (17-21).
Therefore, in the current study, HAV, HBV, and HCV-negative
cases might be infected with other hepatitis viruses. Thus,
further investigation is required for better understanding
of the role and epidemiology of viral hepatitis in extension
and transmission of liver diseases.
According to the data from the centers for disease con-
trol and prevention (CDC), Iran is an endemic region for
HAV infection and there is no significant difference in gen-
ders (2, 22, 23). In the current study, the overall seropreva-
lence of anti-HAV and HAV RNA was 32.6% and 28%, respec-
tively, and phylogenetic analysis suggested that all HAV iso-
lates belonged to genotype IB. The mean age of patients
with acute HAV infection was lower than those with acute
hepatitis B or C (Table 2). The mean of ALT and AST levels in
HAV-infected cases were higher than those with HBV and
HCV infections (Table 2). Considering several studies, the
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Figure 4. A phylogenetic tree based on 393 nt of the HBV S region. The bootstrap neighbor joining method with 1000 replicates was performed to determine the evolutionary
distances. HBV genotype C was utilized as an out-group. Sequences are defined by accession number/year/origin of the strain, respectively. The sequences related to this study
are marked.
prevalence of HAV in the country was about 51% to 66% and
as Nejati et al. published in 2012, the predominant circu-
lating genotype was IB (12, 23). However, further epidemio-
logical studies are needed to clarify HAV diversity in other
regions of Iran. In this study, the associated risk factor for
HAV infections was found to be in touch or close contact
with an infected relative, but after multivariate analysis us-
ing logistic regression, no significant difference was found
(Tables 3 and 4). Hepatitis A Virus is transmitted primarily
by the fecal-oral route, and vaccination along with health
education for improving the sanitation, is the most suc-
cessful way to control the infection in endemic areas.
Iran is classified as an area with low to intermediate
prevalence of HBV. The estimated rate of HBV infection in
this country is about 3%, and is higher in males than fe-
males (2.55% versus 2.03%, respectively). Previous epidemi-
ological studies indicated that HBV genotype D is the most
prevalent genotype in Iran (24-28). In the current study,
the S region was analyzed to determine HBV genotypes
and data revealed that all HBV sequences had molecular
characteristics of genotype D. Compared with the RefSeq
and original GenBank resources, five substitutions were
found at the nucleotide level, G362T, C391G, A543C, T562C,
and C584G, all of which were missense (C121F, R131G, Q181H,
S188P and S195W). In the current study, the multivariable
analysis showed that the risk of acute hepatitis B infection
increased nearly 5 times by traveling to the endemic area
(Table 3 and 4). Hepatitis B Virus transmits by contact with
contaminated body fluids, such as blood, blood products,
and semen. The national HBV vaccination program for
newborn and healthcare workers in Iran was started since
1993. However, a major proportion of community is unvac-
cinated and susceptible to the infection. Therefore, HBV
vaccination as well as consultation services about the seri-
ous risks of blood-borne pathogens among unvaccinated
people traveling to areas with intermediate or high preva-
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Figure 5. Neighbor-joining phylogenetic tree for core region of HCV genotype 1 (A) and HCV genotype 3 (B). Bootstrap values for 1000 replicates are given on the branches as
percentages. HCV genotype 6 was utilized as an out-group. All sequences are defined by accession number / year / origin of the strain, respectively. The obtained strains from
this study are marked.
lence of HBV infection is essential.
In the present study, HCV prevalence rate was esti-
mated through the amplification of 5’-UTR, a highly con-
served region among all genotypes, especially genotypes 1
to 6. Since the study of sequence diversity among different
isolates is crucial, especially for analyzing response to ther-
apy, sequencing of other regions, such as core and NS5B, is
recommended for achieving high accuracy of virus dynam-
ics and genotyping (29-32). Iran is categorized as a low-HCV
prevalence region and HCV seroprevalence can vary from
0.08% to 1.6% in different provinces (32-34). Like many Eu-
ropean countries, the predominant HCV genotypes among
Iranian patients are 1 and 3, while in other Middle East
countries, the main genotype is 4. During the recent years,
the pattern of HCV genotypes has changed in the country
and a shift in prevalent subtype from 1a to 3a was noticed.
The current results are in line with this observation
and genotype 3a was found as the most prevalent HCV
genotype (61.7%). This is probably associated with the in-
crease of Intravenous Drug Users (IDUs) and needle shar-
ing, since genotype 3 is commonly found in IDUs. Accord-
ing to the reports of CDC, Intravenous (IV) drugs and nee-
dle sharing are the most common risk factors for infection
with HCV in many countries. However, the current results
Jundishapur J Microbiol. 2018; 11(5):e63317. 7
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Table 3. Univariate Logistic Regression for Associated Risk Factors with Viral Hepatitisa
Risk Factor HAV HBV HCV
Neg. Pos. P Value OR Neg. Pos. P Value OR Neg. Pos. P Value OR
Infected relative 0.042 3.43 0.966 0.96 0.287 0.32
No 103 (95.4) 36 (85.7) 113 (92.6) 26 (92.9) 106 (91.4) 33 (97.1)
Yes 5 (4.6) 6 (14.3) 9 (7.4) 2 (7.1) 10 (8.6) 1 (2.9)
Dental care 0.695 1.21 0.903 1.07 0.410 0.68
No 21 (19.4) 7 (16.7) 23 (18.9) 5 (17.9) 20 (17.2) 8 (23.5)
Yes 87 (80.6) 35 (83.3) 99 (81.1) 23 (82.1) 96 (82.8) 26 (76.5)
Surgery 0.001 0.03 0.096 0.41 0.009 2.87
No 62 (57.4) 41 (97.6) 80 (65.6) 23 (82.1) 86 (74.1) 17 (50)
Yes 46 (42.6) 1 (2.4) 42 (34.4) 5 (17.9) 30 (25.9) 17 (50)
Blood transfusion 0.244 0.40 0.27 0.31 0.438 0.54
No 96 (88.9) 40 (95.2) 109 (89.3) 27 (96.4) 104 (89.7) 32 (94.1)
Yes 12 (11.1) 2 (4.8) 13 (10.7) 1 (3.6) 1210.3 2 (5.9)
Tattooing 0.003 0.05 0.137 1.96 < 0.001 4.80
No 72 (66.7) 41 (97.6) 95 (77.9) 18 (64.3) 96 (82.8) 17 (50.0)
Yes 36 (33.3) 1 (2.4) 27 (22.1) 10 (35.7) 20 (17.2) 17 (50)
Travelling to endemic
area
0.002 0.10 < 0.001 4.97 0.862 1.08
No 72 (66.7) 40 (95.2) 99 (81.1) 13 (46.4) 87 (75) 25 (73.5)
Yes 36 (33.3) 2 (4.8) 23 (18.9) 15 (53.6) 29 (25) 9 (26.5)
IV drug 0.998 0.00 0.660 0.70 0.058 2.89
No 94 (87) 42 (100) 110 (90.2) 26 (92.9) 108 (93.1) 28 (82.4)
Yes 14 (13) 0 (0.0) 12 (9.8) 2 (7.1) 8 (6.9) 6 (17.6)
aValues are expressed as No. (%).
Table 4. Multiple Logistic Regression for Associated Risk Factors with Viral Hepatitis
Virus Risk Factor B S.E Wald df P Value OR
HAV
Age -0.336 0.066 25.706 1 0.001 0.72
AST 0.050 0.031 2.593 1 0.107 1.05
Tattooing -4.815 3.613 1.776 1 0.183 0.01
IV drug -19.506 8556.313 0.000 1 0.998 0.00
Constant 5.484 3.487 2.473 1 0.116 240.74
HBV
AST -0.065 0.023 8.046 1 0.005 0.94
Surgery -1.263 0.573 4.865 1 0.027 0.28
Travelling to endemic area 1.594 0.477 11.169 1 0.001 4.92
Constant 3.978 1.988 4.003 1 0.045 53.41
HCV
Age 0.099 0.030 11.123 1 0.001 1.10
Tattooing 1.274 0.446 8.179 1 0.004 3.58
Constant -5.238 1.142 21.024 1 0.001 0.01
indicated that tattooing has a significant relationship with
HCV infection in Ahvaz city and can increase the risk of in-
fection by 3.5 times (Table 4). It has been declared that the
risk of HCV infection rises with increasing of covered ar-
eas and the number of tattoos (35). Since tattooing is espe-
cially popular among young people, a comprehensive ed-
ucational program should be performed about the impor-
tant risk of blood borne infections for the youth commu-
nity.
6. Conclusions
The current study showed the molecular epidemiology
of circulating viral hepatitis in the country and may con-
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tribute to the information on the genetic diversity of viral
hepatitis worldwide. It can also underlines the necessity
of further studies and evaluation of preventive programs,
such as rigorous screening and treatment, vaccination in
high risk groups, social services like the needle exchange
program (NEP) and consultation among young people to
reduce risk factors in the country.
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